CBER’s Division of Emerging and Transfusion Transmitted Diseases (DETTD) will fund BioTrove’s efforts to adapt the center’s current real-time PCR pathogen assays to BioTrove’s SNAP system and to perform the technical validation of the SNAP system’s performance, one of several platforms that CBER is evaluating for high throughput, multi-plex detection of blood-borne pathogens.
FDA is interested in the SNAP system because of its potential to detect multiple pathogens at once in a single sample. Successful adaptation and validation of the system could help DETTD assist in the development of standardized, reproducible quantitative measurement tools to monitor the safety of the nation’s blood supply.
BioTrove’s SNAP system has the potential to detect multiple pathogens at one time in a single sample by combining BioTrove’s OpenArray nanofluidic PCR platform with Gene Express’s Standardized RT-PCR (StaRT-PCR) standards method controls, and TaqMan fluorogenic-labeled probes. The combined systems have shown initial success in providing researchers a dynamic range of standard real-time quantitative PCR in addition to simplifying the workflow and reducing the quantity of the test sample. These are important considerations for rapid and accurate determination of the safety of donated blood to be used in patients.
“BioTrove is committed to providing support and assistance to the DETTD as it carries out its own mission to protect the nation’s blood supply,” said Albert A. Luderer, Ph.D., president and chief executive officer, BioTrove. “Initial plans are to test several viruses, bacteria and parasites deemed priority infectious pathogens on the OpenArray SNAP platform, and contingent upon initial success, a second-year project may be proposed.”
